The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer

  • Lee, Kyoung Ju (Division of Respiratory and Allergy, Department of Internal Medicine, Daejin Medical Center) ;
  • Lee, Eun Joo (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • Hur, Gyu Young (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • Lee, Sang Yeub (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • Kim, Je Hyeong (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • Shin, Chol (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • Shim, Jae Jeong (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • In, Kwang Ho (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • Kang, Kyung Ho (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • Yoo, Se Hwa (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center) ;
  • Lee, Sung Yong (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University Medical Center)
  • Published : 2013.07.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Chemotherapy combined with radiation therapy is the standard treatment for limited stage small cell lung cancer (LS-SCLC). Although numerous studies indicate that the overall duration of chemoradiotherapy is the most relevant predictor of outcome, the optimal chemotherapy and radiation schedule for LS-SCLC remains controversial. Therefore we analyzed the time from the start of any treatment until the end of radiotherapy (SER) in patients with LS-SCLC. Methods: We retrospectively analyzed 29 patients diagnosed histologically with LS-SCLC and divided them into two groups: a short SER group (< 60 days) and a long SER (> 60 days) group. Patients were treated with irinotecan-based chemotherapy and thoracic radiotherapy. Results: Sixteen patients were in the short SER group and 13 patients were in the long SER group. Short SER significantly prolonged survival rate (p = 0.03) compared with that of long SER. However, no significant differences in side effects were observed. Conclusions: Short SER should be considered to improve the outcome of concurrent chemoradiotherapy for LS-SCLC.

Keywords

References

  1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544. https://doi.org/10.1200/JCO.2005.04.4859
  2. Stupp R, Monnerat C, Turrisi AT 3rd, Perry MC, Leyvraz S. Small cell lung cancer: state of the art and future perspectives. Lung Cancer 2004;45:105-117. https://doi.org/10.1016/j.lungcan.2003.12.006
  3. De Ruysscher D, Vansteenkiste J. Chest radiotherapy in limited-stage small cell lung cancer: facts, questions, prospects. Radiother Oncol 2000;55:1-9.
  4. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-271. https://doi.org/10.1056/NEJM199901283400403
  5. Kumar P. The role of thoracic radiotherapy in the management of limited-stage small cell lung cancer: past, present, and future. Chest 1997;112(4 Suppl):259S-265S. https://doi.org/10.1378/chest.112.4_Supplement.259S
  6. Anderson B, Murray D. Clinical Relevant Resistance in Cancer Chemotherapy. 1st ed. Boston: Springer, 2006.
  7. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-146. https://doi.org/10.3109/02841868809090333
  8. Tarnawski R, Fowler J, Skladowski K, et al. How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys 2002;54:229-236.
  9. Bentzen SM, Thames HD. Clinical evidence for tumor clonogen regeneration: interpretations of the data. Radiother Oncol 1991;22:161-166. https://doi.org/10.1016/0167-8140(91)90019-D
  10. Bernier J, Bentzen SM. Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer 2003;39:560-571. https://doi.org/10.1016/S0959-8049(02)00838-9
  11. Overgaard J, Hansen HS, Specht L, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003;362:933-940. https://doi.org/10.1016/S0140-6736(03)14361-9
  12. Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer: what limits limited disease? Lung Cancer 2002;37:271-276. https://doi.org/10.1016/S0169-5002(02)00072-7
  13. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006;24:1057-1063. https://doi.org/10.1200/JCO.2005.02.9793
  14. Mazumdar M, Smith A, Schwartz LH. A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol 2004;57:358-365. https://doi.org/10.1016/j.jclinepi.2003.07.015
  15. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91. https://doi.org/10.1056/NEJMoa003034
  16. Bentzen SM. Repopulation in radiation oncology: perspectives of clinical research. Int J Radiat Biol 2003;79:581-585. https://doi.org/10.1080/09553000310001597002
  17. Budach W, Paulsen F, Welz S, et al. Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma. Br J Cancer 2002;86:470-476. https://doi.org/10.1038/sj.bjc.6600081
  18. Davis AJ, Tannock JF. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 2000;1:86-93. https://doi.org/10.1016/S1470-2045(00)00019-X
  19. Wu L, Tannock IF. Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-f luorouracil. Cancer Res 2003;63:2134-2138.
  20. Pijls-Johannesma MC, De Ruysscher D, Lambin P, Rutten I, Vansteenkiste JF. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev 2005;(1):CD004700.
  21. Jones B. Rapid repopulation in radiotherapy: a debate on mechanism. Radiother Oncol 1992;24:124-126. https://doi.org/10.1016/0167-8140(92)90293-4
  22. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997;15:893-900. https://doi.org/10.1200/JCO.1997.15.3.893
  23. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-3060. https://doi.org/10.1200/JCO.2002.12.071
  24. Bunn PA Jr, Lichter AS, Makuch RW, et al. Chemotherapy alone or chemotherapy with chest radiation therapy in limited stage small cell lung cancer: a prospective, randomized trial. Ann Intern Med 1987;106:655-662. https://doi.org/10.7326/0003-4819-106-5-655
  25. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-1624. https://doi.org/10.1056/NEJM199212033272302
  26. Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000;30:23-36. https://doi.org/10.1016/S0169-5002(00)00127-6
  27. Curran WJ Jr. Combined-modality therapy for limitedstage small cell lung cancer. Semin Oncol 2001;28(2 Suppl 4):14-22.
  28. Jeong HC, Lee SY, Kim JH, et al. Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer. Lung Cancer 2006;53:361-366. https://doi.org/10.1016/j.lungcan.2006.06.002
  29. Klautke G, Fahndrich S, Semrau S, Buscher C, Virchow C, Fietkau R. Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study. Lung Cancer 2006;53:183-188. https://doi.org/10.1016/j.lungcan.2006.04.012

Cited by

  1. Investigating a Correlation between Chemoradiotherapy Schedule Parameters and Overall Survival in a real-life LD SCLC Patient Cohort vol.7, pp.14, 2013, https://doi.org/10.7150/jca.16741